Oncotelic Therapeutics Joint Venture Identifies Biomarker Signature for Precision mTOR Inhibitor Therapy
Key Insights
Sapu Nano (search), a joint venture of Oncotelic Therapeutics (search), has identified a High-RICTOR (search)/Low-RPTOR (search) molecular signature that predicts tumor sensitivity to Sapu003 (search), an intravenous everolimus formulation.
The biomarker framework was developed from analysis of over 9,000 tumor samples across 20 cancer types and represents the first prospective selection strategy for IV everolimus therapy.
mTORC2 (search)-dominant tumors showing this signature include HR+/HER2- breast cancer (search), lung adenocarcinoma (search), gastric cancer (search), renal cancer (search), ovarian cancer (search), AML, and T-cell malignancies (search).
Oncotelic Therapeutics (search), Inc. (OTCQB: OTLC) announced that its 45% owned joint venture, Sapu Nano (search), has identified a High-RICTOR (search)/Low-RPTOR (search) molecular signature that predicts tumor sensitivity to Sapu003 (search), the company's intravenous Deciparticle formulation of everolimus. This biomarker framework, based on analysis of more than 9,000 tumor samples across 20 cancer types, represents the first prospective selection strategy for IV everolimus and will be presented at the 2025 San Antonio Breast Cancer Symposium.
Biomarker Discovery Enables Precision Patient Selection
Data show that mTORC2 (search)-dominant tumors exhibit heightened mTOR (search) dependency and predicted sensitivity to Sapu003 (search). These tumors include HR+/HER2- breast cancer (search), lung adenocarcinoma (search), gastric cancer (search), renal cancer (search), ovarian cancer (search), acute myeloid leukemia (search) (AML), and T-cell malignancies (search). The identification of this biomarker signature could enable clinicians to select patients most likely to benefit from the treatment, potentially improving outcomes while reducing unnecessary exposure to therapy for those unlikely to respond.
The research represents a significant step forward in understanding mTOR (search) pathway biology and its role in cancer progression. mTORC2 (search)-dominant tumors appear to have distinct molecular characteristics that make them particularly vulnerable to targeted mTOR inhibition. This discovery could lead to more effective treatment strategies for several cancer types that currently have limited therapeutic options, particularly those identified as having the High-RICTOR (search)/Low-RPTOR (search) signature.
Advanced Drug Delivery Technology
Sapu003 (search) overcomes limitations of oral everolimus through higher tissue penetration, reduced gastrointestinal accumulation, and preserved metabolic specificity. The intravenous formulation represents a significant advancement in mTOR (search) inhibitor delivery, addressing challenges that have limited the effectiveness of oral formulations in certain cancer types. Using Sapu Nano (search)'s proprietary Deciparticle technology, Sapu003 delivers everolimus directly into the bloodstream.
"The approval of Sapu003 (search) to enter human trials is a landmark moment. By enabling full drug absorption through intravenous delivery, this program has the potential to achieve meaningful tumor shrinkage where oral formulations have been limited," said Dr. Sud Agarwal, CEO of Ingenu (search), a contract research organization in Australia. "We are proud to support Sapu Nano (search) in advancing this therapy, potentially giving breast cancer patients better outcomes and improved quality of life."
Clinical Trial Advancement
Sapu Nano (search) recently secured approval from Australia's Human Research Ethics Committee to begin enrolling patients in clinical trials for Sapu003 (search) as an injectable form of Afinitor (everolimus) for breast cancer treatment. The biomarker discovery comes from extensive genomic analysis available through resources like the company's research portal, which provides access to comprehensive tumor data.
Implications for Precision Oncology
The identification of this predictive biomarker has important implications for precision oncology, potentially enabling more targeted use of mTOR (search) inhibitors in cancer treatment. By identifying which patients are most likely to respond to Sapu003 (search), clinicians could optimize treatment strategies and improve therapeutic outcomes. This approach aligns with the broader trend in oncology toward personalized medicine, where treatments are selected based on individual tumor characteristics rather than a one-size-fits-all approach.
As the research moves toward clinical application, the biomarker framework could help streamline clinical trial design by enabling more precise patient selection. This could accelerate the development of Sapu003 (search) and potentially improve success rates in clinical testing. The findings also contribute to the growing body of knowledge about mTOR (search) signaling in cancer, which could inform the development of additional targeted therapies for mTOR-dependent tumors.